ABSI compared with PRME: revenue, margins and what each company keeps, and the suppliers and customers both name

ABSIAbsci Corp

Mkt capRevenueRevenue

PRMEPrime Medicine, Inc.

Mkt capRevenueRevenue

Compare

ABSIAbsci Corp

PRMEPrime Medicine, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ABSI

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.9%▲+0.96%×0.07

May 8 '26±14.2%▲+2.61%×0.18

Q1 FY26±19.5%▼−2.99%×0.15

Q3 FY25±13.8%▼−22.35%×1.62

PRME

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.2%▼−4.22%×0.30

May 7 '26±15.5%▼−8.65%×0.56

= impliedABSI realized, solidPRME realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±18.4%

▼−9.23%

×0.50

Q3 FY25±17.6%▼−8.85%×0.50

ABSIAbsci Corp

11.12▼−8.10%· post 11.21

Mkt cap$1.9BRevenue$650,000Q4 FY25Revenue$3MFY25

PRMEPrime Medicine, Inc.

4.72▼−9.92%· post 4.71

ClosedOct 30 '26

Mkt cap—Revenue$1MQ2 FY26Revenue$5MFY25

Compare

ClosedOct 30 '26

ABSIAbsci Corp

PRMEPrime Medicine, Inc.

11.12▼−8.10%post 11.21

Price

4.72▼−9.92%post 4.71

$1.9B

Mkt cap

—

Q4 FY25$650,000

Revenue

$1MQ2 FY26

FY25$3M

Revenue

$5MFY25

ABSI11.12▼−8.10%vsPRME4.72▼−9.92%ClosedOct 30 '26